Upstream Bioprocessing Market Analysis

Upstream Bioprocessing Market Analysis

To get key market trends

  Download Free Sample

Based on product, the market is segmented into bioreactors/ fermenters, cell culture products, filters, bioreactor accessories, bags & containers, and other products. The bioreactors/fermenters segment accounted for highest market share of 48.6% in 2023.
 

• Bioreactors/ fermenters are the primary vessels used for cell culture, which is the foundational process in upstream bioprocessing. These vessels provide a controlled environment for the growth and proliferation of cells or microorganisms, essential to produce biopharmaceuticals, enzymes, vaccines, and other bioproducts.
   
• Additionally, their scalability, flexibility and precise process control and monitoring collectively contributes to the growth of this segment.
   

Based on usage mode, the upstream bioprocessing market is classified into multi-use and single-use. The multi-use segment dominated the market and is anticipated to showcase growth at 9.1% CAGR over the coming years.
 

• Multi-use equipment are known for their durability and reliability, allowing for multiple cycles of operation without compromising performance, therefore makes them a preferred choice for many bioprocessing facilities.  
   
• Further, the versatility of multi-use equipment allows for its application in various stages of bioprocessing, from cell culture and fermentation to downstream processing. This adaptability enhances its value proposition for bioprocessing facilities seeking comprehensive solutions for their production needs.
   

Based on mode, the upstream bioprocessing market is categorized into in-house and outsourced. The in-house segment is expected to reach USD 11.8 billion by 2032.
 

• Companies benefit from in-house bioprocessing facilities, which offer increased operational flexibility and agility to adapt to evolving market dynamics and shifts in product demand.
   
• Moreover, these facilities empower companies to uphold rigorous quality control standards and adhere to regulatory requirements seamlessly throughout the entire manufacturing process. Due to these advantages over outsourced bioprocessing, the in-house segment is anticipated to experience growth.
   

Based on application, the upstream bioprocessing market is divided into monoclonal antibody production, vaccine production, cell & gene therapy production and other applications. The monoclonal antibody production segment accounted for USD 4.9 billion in 2023.
 

• The monoclonal antibodies (mAb) production segment held the highest market share in upstream bioprocessing due to its therapeutic importance, widespread clinical adoption, technological advancements, scalability, regulatory support, and diverse applications across various therapeutic areas.
   
• Additionally, the proven efficacy, safety, and market demand for mAb-based therapies, coupled with optimized production processes, have solidified mAb production in the biopharmaceutical industry, thereby fostering its dominance in upstream bioprocessing.
   

Based on end-user, the upstream bioprocessing market is classified into biopharmaceutical companies, CDMOs & CROs, and research & academic institutes. The biopharmaceutical companies segment is projected to grow at CAGR of 9.4% between 2024 and 2032.
 

• Biopharmaceutical companies are specialized in developing and manufacturing biological products, including monoclonal antibodies, vaccines, and recombinant proteins, thereby witnessing a surge in demand for their products. This demand necessitates upstream bioprocessing, leading to heightened adoption of such processes to maximize operational efficiency and product quality.
   
• Furthermore, vertical integration within biopharmaceutical companies enables seamless integration of upstream and downstream processing, optimizing overall manufacturing efficiency and reducing costs. These factors contribute to the dominance of biopharmaceutical companies in the market.
   

North America upstream bioprocessing market is estimated to reach over USD 9.5 billion by the end of forecast timeline.
 

• The increasing collaboration and partnerships with an aim of increasing awareness and education related to bioprocessing is expected to support the growth of this market. For instance, in 2018, Jefferson (Philadelphia University + Thomas Jefferson University) announced partnership with National Institute for Bioprocessing Research and Training (NIBRT) for creating Jefferson Institute for Bioprocessing, the first – and only – education and training institute for biopharmaceutical processing in North America.